A Phase II Evaluation of Cetuximab (Erbitux, C225, NSC 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix.

Trial Profile

A Phase II Evaluation of Cetuximab (Erbitux, C225, NSC 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2015

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jul 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
    • 28 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Jun 2009 New source identified and integrated (Oregon Health and Science University Cancer Institute).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top